Biogen Ramping Up For Antegren Launch; Relapsed MS Patients One Target
Biogen Idec expects to position Antegren to multiple sclerosis patients who are experiencing breakthrough disease upon approval of the monoclonal antibody
Biogen Idec expects to position Antegren to multiple sclerosis patients who are experiencing breakthrough disease upon approval of the monoclonal antibody